How is BPC-157 dosed and mixed?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Most often logged by Milligram users
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds BPC-157 and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    A review describes off-label BPC-157 doses as typically 200 to 500 µg a day under the skin or by mouth, extrapolated informally from rodent doses without formal allometric scaling,1 and 500 mcg is the dose most often logged in Milligram (49%).11

    The guide's example

    500 mcg of BPC-157 from a 10 mg vial mixed with 2 mL is 10 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water3 mL of water
    5 mg17% set up115 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units2.5 mg/mL: 250 mcg is 10 units, 500 mcg is 20 units1.667 mg/mL: 250 mcg is 15 units, 500 mcg is 30 units
    10 mg69% set up1110 mg/mL: 250 mcg is 2.5 units, 500 mcg is 5 units5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units3.333 mg/mL: 250 mcg is 7.5 units, 500 mcg is 15 units
    20 mg8% set up1120 mg/mL: 250 mcg is 1.3 units, 500 mcg is 2.5 units10 mg/mL: 250 mcg is 2.5 units, 500 mcg is 5 units6.667 mg/mL: 250 mcg is 3.8 units, 500 mcg is 7.5 units

    Most often logged by Milligram users: 500 mcg, 49% logged.11

    Jump to a vial 5 mg 10 mg 20 mg

    Mixing a vial and reading units

    500 mcg of BPC-157 from a 10 mg vial mixed with 2 mL is 10 units on a U-100 syringe.

    41% set up 10 mg + 2 mL11

    Of the people who set up a BPC-157 vial in Milligram, 69% logged 10 mg, 17% 5 mg and 8% 20 mg.11 The mix most often set up was 10 mg with 2 mL (41%).11 Of the people who logged a draw, 40% set up 500 mcg at 10 units and 8% 500 mcg at 20 units.11 FDA's briefing gives the water solubility of BPC-157 free base as 5 mg/mL and names no diluent for mixing; one product it describes is a 10 mg per 5 mL injection kit sold for self-administration at home, and the mixing guide covers the steps.2 FDA gives the same 5 mg/mL for the acetate; the table's more concentrated cells sit above the water solubility FDA states.2

    The calculator is at the top of the page

    What reviews, trials and logs give for dose

    A DailyMed search for BPC-157 returned no product label, and FDA's briefing states there is no approved product containing BPC-157-related substances in any country at this time.32 None of the human studies or registered trials reviewed here gives a stepped schedule. FDA says the human studies it found were short, small and tested doses likely exploratory in nature.2

    TrialDose and schedulePeopleLength
    NCT02637284 (start 2015), oral tablets1 mg tablets or placebo: a single dose of 1, 3 or 6 tablets (phase 1a), or 3 tablets three times daily (phase 1b); status unknown, no results posted4242 healthy volunteers aged 18 to 35 (estimated)Single dose (phase 1a); 2 weeks (phase 1b)
    Veljaca et al., enema studyUp to 2 mg/kg rectal enema once daily, or placebo224 healthy people on BPC-157 (32 randomised)8 days
    Ruenzi et al., enema trial80 mg rectal enema once daily, or placebo253 people with mild to moderate ulcerative colitis randomised 1:1 (about 26 on BPC-157)2 weeks
    Lee and Padgett, knee pain chart review2-4 mg injected into the knee joint, BPC-157 alone or combined with TB4; the dose is FDA's summary, as the paper gives none2517 people with knee pain (16 reached; 12 had BPC-157 alone, 4 with TB4)1-2 doses
    Lee et al., interstitial cystitis pilot10 mg in total, injected around the bladder in one procedure6212 women with interstitial cystitis, aged 39 to 76One procedure
    Lee and Burgess, intravenous pilot10 mg on day 1 and 20 mg on day 2, each in 250 cc of normal saline infused over one hour722 healthy adults, each given intravenous BPC-157 beforeTwo days
    NCT07752381, gummies500 µg per serving, two gummies daily by mouth, as a dietary supplement with no comparator group840 physically active adults8 weeks

    Two registered trials plan daily BPC-157 doses under the skin without stating the dose given: NCT07437547, recruiting, gives BPC-157 or placebo once daily for 14 days to people with a grade II hamstring strain (120 people estimated), and in NCT07803250, not yet recruiting, participants give themselves BPC-157 or saline daily for 90 days after rotator cuff repair (30 estimated in the enrollment field, twenty in the summary).910

    In Milligram, 49% of people logged a 500 mcg dose and 18% logged 250 mcg.11 By unit, 71% logged mcg, 24% mg and 5% IU.11

    How long BPC-157 keeps before and after mixing

    FDA's briefing reports, citing a reference, that lyophilized BPC-157 free base is stable at room temperature for 3 weeks but is recommended to be stored desiccated below -18°C, because moisture greatly decreases the long-term stability of lyophilized peptides.2 After mixing, it reports the free base in solution is stable for 2-3 weeks at 4°C and for 3-4 months at -20°C, without naming a diluent.2

    A review notes that adsorption to container surfaces is the most consequential physical degradation risk and has not been quantified.1 The label searches run for this guide returned no BPC-157 label, so no label gives storage conditions for a mixed vial.

    Frequently asked questions

    What strengths does BPC-157 come in?

    FDA's briefing reports websites selling BPC-157 injection products of 5, 6 and 10 mg and a 10 mg per 5 mL injection kit, and an adverse event report involving a compounded 15 mg per vial injection.2 The two nominators of BPC-157 for compounding, whose nominations were later withdrawn, proposed oral capsules of 250 μg, 500 μg and 1 mg and a subcutaneous injection of 2,000 μg/mL.2

    Which routes do people log for BPC-157?

    In Milligram, 92% of people logged under the skin and 4% logged oral.11 FDA found no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal doses.2

    How the logged figures are counted

    Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

    References

    1. Pharmaceutics. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. 2026. pmc.ncbi.nlm.nih.gov
    2. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (BPC-157). 2026. fda.gov
    3. US National Library of Medicine (DailyMed). DailyMed label search for BPC-157. 2026. dailymed.nlm.nih.gov
    4. ClinicalTrials.gov. NCT02637284: Phase I pilot of PCO-02 (BPC-157) in healthy volunteers. 2015. clinicaltrials.gov
    5. Alternative Therapies in Health and Medicine. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. 2021. pubmed.ncbi.nlm.nih.gov
    6. Alternative Therapies in Health and Medicine. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. 2024. pubmed.ncbi.nlm.nih.gov
    7. Alternative Therapies in Health and Medicine. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. 2025. pubmed.ncbi.nlm.nih.gov
    8. ClinicalTrials.gov. NCT07752381: Peptide gummies containing BPC-157. 2026. clinicaltrials.gov
    9. ClinicalTrials.gov. NCT07437547: Phase 2 trial of BPC 157 for acute grade II hamstring strain. 2026. clinicaltrials.gov
    10. ClinicalTrials.gov. NCT07803250: BPC-157 after rotator cuff repair surgery. 2026. clinicaltrials.gov
    11. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted